Four novel candidate drug targets, AIM1, ERGIC1, TMED3, and TPX2, were selected for further studies based on the high expression in prostate cancer compared to normal prostate and all other normal tissues included in GeneSapiens database (Supporting Figure S1), as well as their novelty as regulators of prostate cancer cell proliferation and apoptosis. Here, TMED3 is linked to prostate carcinoma.